Coolips

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Coolips

Property Description
Active ingredient Cetirizine Hydrochloride
Form Tablets, Oral solution, Syrup
Pharmacological class Second-generation Antihistamine
Common use Systemic anti-allergic relief
Origin Synthetic

What Type of Medicine is Coolips? (Classification and Origin)

Coolips is a synthetic pharmaceutical preparation that belongs to the antihistamine class of medicines, specifically identified as a second-generation H1-receptor antagonist. This pharmacological classification is clinically recognized for targeting histamine receptors in the periphery, supporting its use as an effective anti-allergic agent. This second-generation status denotes a modern formulation designed to provide relief while minimizing the notable sedative effects often associated with older antihistamine compounds. Cetirizine is a potent, selective histamine H1-receptor antagonist with recognized efficacy.

Composition: The Role of Cetirizine Hydrochloride

The entire therapeutic effect of Coolips is directly attributed to its single active ingredient, Cetirizine Hydrochloride. This substance is a derivative of piperazine, engineered for its targeted anti-allergic properties. Coolips is provided for oral administration in several dosage forms, typically including film-coated tablets, oral solutions, and syrups, which allow for systemic absorption. Cetirizine is indicated as a non-sedating H1-antihistamine. This focus on a single active ingredient allows for precise therapeutic intervention when managing isolated allergic conditions.

The General Purpose of Coolips

The general purpose of Coolips is to provide systemic anti-allergic effects by mitigating the physiological response to hypersensitivity triggers. It achieves this by functioning as a highly selective H1-receptor blocker, competitively binding to these receptors to prevent the natural chemical histamine from attaching. Histamine is the body's primary mediator of immediate allergic symptoms; consequently, by inhibiting this key step, Coolips helps to reduce the overall manifestation of hypersensitivity reactions throughout the body. For instance, Coolips is typically used to manage discomfort arising from common exposure to seasonal allergens like pollen.

Regulatory References

  1. The U.S. National Library of Medicine’s drug information service

What side effects are possible with Coolips?

Official Adverse Reactions and Safety Profile

The safety profile of Coolips (Cetirizine Hydrochloride) is established through clinical trials and post-marketing surveillance, classified according to governmental regulatory frequency categories.

Common Adverse Reactions

Adverse events classified as Common (affecting up to 1 in 10 users) include those related to the Nervous System and General Disorders, such as somnolence (drowsiness), fatigue, headache, dizziness, and dry mouth. These effects are generally recognized as mild to moderate.

Rare and Serious Adverse Reactions

The regulatory labels document rare but clinically significant events. Serious adverse reactions officially reported include rare cases of hypersensitivity and anaphylactic shock (Very Rare), which relate to Immune System Disorders. Other rare events include abnormalities in hepatic function tests.

Population-Specific Safety Considerations

The official labeling includes safety statements for certain patient groups. Dosage adjustment is formally required for individuals with renal impairment or hepatic impairment due to altered drug clearance. Additionally, caution is noted for older adults and those with conditions that may predispose them to urinary retention.

Exposure-Related Safety Patterns

The regulatory safety notes address potential effects linked to duration of use. Reports indicate that pruritus (itching) and/or urticaria may occur upon discontinuation of the medicine, especially after long-term daily use. Furthermore, concurrent use with alcohol or other Central Nervous System (CNS) depressants may result in additional reductions in alertness, a formal safety restriction.

Overdose and Emergency Response

The official regulatory documents state that an overdose of Coolips (Cetirizine Hydrochloride) may present with a variety of documented clinical manifestations. The symptom profile spans effects on the central nervous system (CNS), including somnolence, restlessness, agitation, confusion, and in severe cases, stupor or coma. Non-CNS findings include tachycardia (fast heart rate), tremor, diarrhea, headache, malaise, and urinary retention. Severe outcomes such as seizures have been reported in official labeling, with events documented following intake of at least five times the recommended daily dose.

Immediate medical help must be sought if an overdose is suspected. Regulatory guidance mandates contacting emergency services if severe, life-threatening symptoms—such as a seizure, collapse, or difficulty breathing—occur. This requirement to seek immediate medical attention is a central component of the official guidance.

Management of an overdose is primarily symptomatic and supportive, as there is no known specific antidote listed in the prescribing information. Regulatory documents further note that the compound is not effectively removed by hemodialysis, and cardiac monitoring may be necessary in the context of large overdoses. Specific considerations exist for certain populations; for instance, overdose presentation in children may involve initial irritability followed by drowsiness, and caution is noted for patients with impaired kidney function.

Therapeutic Uses of Coolips

What Coolips Treats: Main Uses and Benefits

Coolips is commonly used to help manage symptoms related to heightened physiological activity across multiple therapeutic domains, with its primary use centered on allergic manifestations. The medication is considered relevant for easing the nasal and ocular symptoms of seasonal and perennial allergic rhinitis, alongside chronic urticaria.

The medication is commonly used across therapeutic domains, including situations involving symptomatic discomfort related to seasonal allergic rhinitis, perennial allergic rhinitis, and chronic idiopathic urticaria. It is applied in clinical settings that involve acute or unstable symptom patterns, such as during high pollen seasons or following sudden allergen exposure.

“It offers symptomatic relief that helps patients cope more steadily with these distressing manifestations.”

This medication plays a role in managing symptom clusters that interfere with daily functioning, is relevant for easing symptoms that create noticeable functional strain, such as repeated sneezing, persistent runny nose (rhinorrhea), and concurrent itching and watering of the eyes, as well as the generalized pruritus and hives associated with skin reactions. This supportive relief contributes to easing the overall symptom load during periods of heightened discomfort.

Quick Fact: Relief for Allergic Symptom Clusters Coolips is commonly used to help with symptom clusters that may become intense or disruptive, including those affecting the eyes, nose, and skin, supporting patients in maintaining day-to-day comfort.

Eligibility and Restrictions for Use

The eligibility profile for Coolips is strictly defined by regulatory documents, focusing on patient characteristics and underlying conditions.

Contraindicated Populations

Use of the medicine is absolutely forbidden in any individual with a history of hypersensitivity to Cetirizine Hydrochloride, its parent compound Hydroxyzine, or related piperazine derivatives. It is also contraindicated in patients presenting with severe renal failure, specifically where creatinine clearance is measured at less than 10 mL/min.

Age-Related Eligibility

The medicine is approved for adolescents and adults. The film-coated tablet formulation is not recommended for children under six years of age as it does not allow for necessary dose adaptation. Pediatric formulations are generally used for younger age groups based on local regulatory guidelines.

Condition-Based Restrictions

Eligibility is restricted in patients with hepatic impairment or moderate renal impairment. Additionally, caution is officially advised for patients with a predisposition to urinary retention or those with epilepsy/risk of convulsions.

Reproductive Status

The use in nursing mothers is not recommended due to the drug being excreted into human milk. Eligibility during pregnancy is restricted and limited to situations where the use is determined to be clearly needed.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes the officially documented interaction patterns for Coolips (Cetirizine Hydrochloride) as described in government regulatory documentation.

Pharmacodynamic Interactions

The most prominent regulatory caution involves Central Nervous System (CNS) Depressants and alcohol. Co-administration with these substances may lead to an additive pharmacodynamic effect, resulting in additional reductions in alertness and further impairment of CNS performance. This restriction is based on the potential for the effects of both substances to combine.

Pharmacokinetic Interactions

Coolips has a notably limited pharmacokinetic interaction profile. It is documented to have minimal interaction potential with drugs metabolized by the major hepatic cytochrome P450 enzyme system.

A specific, measurable pharmacokinetic interaction occurs with Theophylline (at a 400 mg once-daily dose), which results in a 16% decrease in Coolips' clearance; however, this finding is generally classified by regulatory authorities as not clinically significant.

Food and Population-Specific Notes

Food intake is documented to delay the time to peak concentration and reduce the peak concentration of Coolips, though the overall extent of absorption (AUC) remains unchanged. Furthermore, official labeling includes a population-specific constraint regarding severe renal impairment. In this patient group, the drug's reduced clearance leads to a risk of increased systemic exposure to Coolips itself.

Mechanism of Action

How Coolips Works

Coolips acts through a targeted, selective mechanism on specific biological processes. Its mechanism of action is based on molecular intervention in defined signaling pathways, resulting in the modulation of dysregulated physiological responses.


Targeted Modulation and Signal Transduction

Coolips initiates its effect by selectively engaging a defined receptor or enzyme system, primarily within central or peripheral pathways. This targeted binding modulates the receptor's activity, influencing early molecular steps that define subsequent pathway engagement. Following the initial interaction, the drug operates within well-characterized molecular cascades to reduce excessive signaling. Coolips modifies these signal sequences, resulting in a reduction of overactive or dysregulated cellular communication, which is common in systems where pathway activation is persistent.


Resulting Physiological Regulation

This mechanism ultimately results in a more balanced and regulated state within the targeted pathways. The influence on these core mechanistic domains leads to the stabilization of overactive physiological responses, thereby contributing to the drug's overall pharmacological effect.

Dosage and Administration Information

Instruction Map: How to use Coolips — Administration Guidelines


Administration Scope

Route of administration: The medication is primarily delivered via the Oral route (tablets, solution, or syrup). An Intravenous (IV) injection formulation is also available for use in acute, supervised settings.

Dosing schedule: The standard dose for adults and adolescents (12 years and older) is 10 mg taken once daily, which represents the maximum recommended daily intake. A 5 mg dose may be used for less severe conditions.

Timing in relation to meals (if applicable): Oral forms may be administered with or without food.

Preparation requirements (if applicable): Oral tablets must be swallowed whole with liquid. Liquid forms require a calibrated syringe or spoon for accurate measurement.

Age-group administration rules: Patients 12 years and older follow the standard 10 mg once daily dose. Dosing for individuals with impaired kidney function requires reduction; for example, moderate impairment necessitates 5 mg once daily, and severe impairment requires 5 mg once every two days.

Missed-dose rules: If a dose is missed, it should be skipped if it is close to the next scheduled time; the next dose should be taken at the usual time, and compensating with a double dose is not advised.

Special procedural conditions: The intravenous formulation is administered as a slow push, typically over 1 to 2 minutes.


Instruction Classifications (High-Level)

Administration method type (oral / IV / topical / inhaled / etc.): Systemic (Oral, Intravenous).

Frequency pattern (daily / weekly / as-needed, etc.): Once daily.

Use-context constraints: Use is constrained by renal function status; IV use is constrained to acute, short-term intervention.


Resulting Procedural Structure

Standard step sequence:

  • Determine the precise dose based on the patient's age and degree of renal function.
  • Administer the oral dose once daily, ensuring the daily amount does not exceed 10 mg.
  • If using the liquid form, ensure accurate volume is dispensed using the appropriate measuring tool.

Connection to the overall use protocol (2–4 sentences): The instructions establish a standardized, once-daily oral routine for consistent systemic relief. This routine is governed by dose reductions tied to a patient's kidney function to prevent excessive accumulation of the drug. The availability of an IV route represents a separate, short-term protocol reserved for acute intervention, maintaining a clear distinction between maintenance and acute administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Coolips

Evidence for Use in Seasonal Allergic Rhinitis (Hay Fever)

The research exploring the use of Coolips for seasonal allergic rhinitis primarily involves short-term, randomized controlled trials (RCTs). These studies were designed to measure changes in patient-reported outcomes describing perceived discomfort related to seasonal allergic manifestations, examining the cluster of symptoms associated with seasonal allergies, such as sneezing, runny nose, and itchy eyes. The populations observed included adults, adolescents, and children (typically 2 years old and older).

Findings describe patterns observed in the studies, reporting how changes in the severity of symptoms were measured over defined, short time intervals. What remains uncertain is the long-term effects and the maintenance of symptom control across multiple successive allergy seasons, as follow-up durations were limited in the primary research.

Evidence for Use in Perennial Allergic Rhinitis (Year-Round Allergies)

For perennial allergic rhinitis, the research examined studies designed for intermediate follow-up durations. These were typically randomized trials that monitored symptoms over several months. The research examined outcomes related to patient-reported physical discomfort linked to chronic symptoms, such as persistent runny nose or congestion. The findings indicate patterns related to how symptoms evolved in the observed populations over these intermediate periods.

There is limited information for long-term outcomes spanning multiple years, which means the long-term effects are not fully established for continuous use. The variability in symptom intensity inherent to perennial allergies means the evidence quality varies across studies.

Studies in Different Age Groups and Special Populations

Scientific research describes studies that were evaluated in different age groups, including children, adolescents, and adults. Research examined allergic rhinitis in children as young as two years old and studies monitored infants (aged six months and older) for chronic hives. While the results apply to the populations studied, there is limited information specifically focused on the older adult (geriatric) population, meaning data for these certain groups remain insufficient.

Key Studies & References

  1. National Institute for Health and Care Excellence (NICE): Chronic urticaria and angioedema
  2. Research Summary: Efficacy of cetirizine for the prevention of asthma in young children with atopic dermatitis

Frequently Asked Questions (FAQ)

Common questions about Coolips (FAQ)


Q: Is Coolips intended for acute relief or as a long-term maintenance medicine?

Regulatory documents describe that Coolips may be used for both acute relief of symptoms, such as those related to seasonal allergies, and for managing chronic conditions like hives. For chronic conditions, long-term daily use has been associated with managing certain chronic conditions, whereas for acute conditions, it may only be taken as needed.


Q: How quickly should I expect Coolips to start working?

According to the official product information and pharmacological data, the onset of action is generally described as occurring within thirty minutes to one hour after a patient takes the oral form of the medicine. This time frame is based on the drug's typical absorption profile.


Q: Does Coolips interact with or affect birth control pills?

Official interaction information indicates that Coolips does not affect any type of hormonal contraception, including combined oral pills or progestogen-only pills. It is classified as having a minimal potential for pharmacokinetic drug-drug interactions, which is consistent with its regulatory profile.


Q: Is it safe to take Coolips while pregnant, according to official warnings?

Official labeling in many regions advises that use during pregnancy is not recommended unless the benefit is determined to outweigh the potential risk to the fetus. Official warnings state that there are no controlled data from studies in pregnant humans, and use is generally limited to situations where the medicine is clearly needed.


Q: Can Coolips tablets be crushed or split?

For oral administration, the tablets are generally instructed to be swallowed whole with liquid. The regulatory guidance is that the tablets should be swallowed whole to maintain their integrity. Additionally, regulatory handling information indicates that if the tablets are crushed or broken, dust should be avoided due to potential inhalation or contact hazards.


Q: Does Coolips affect sleep patterns?

Official documents list somnolence (drowsiness) and fatigue as common adverse effects. These are known nervous system effects that can impact alertness. Furthermore, research literature and official reports also note changes in the quality of sleep or insomnia as related adverse effects.


Q: What is the main difference between Coolips and [Similar Drug Name]?

Coolips is classified as a second-generation H1-receptor antagonist, placing it within the modern category of antihistamine medicines. This pharmacological classification supports its intended profile of having less likelihood of causing notable sedation compared to older, or first-generation, agents.


Q: Can Coolips be taken long-term?

Official information suggests that long-term use for chronic conditions like hives is possible, with regulatory documents describing its use in these contexts. However, a specific warning exists that severe itching may occur upon stopping long-term daily use of the medication.


Q: Are there any specific foods or drinks I should avoid while taking Coolips?

Alcohol is the primary substance noted to be avoided or limited, as combining it with Coolips may lead to additional reductions in alertness and impairment of performance. While general food intake can affect the timing of the drug’s peak concentration, it does not affect the overall amount absorbed.


Q: Is it normal to feel a change in energy levels after starting Coolips?

Official documentation lists fatigue and excessive tiredness as common adverse reactions that may be experienced by users. This represents a known change in energy level reported in the drug's regulatory labeling.


Q: Can Coolips affect my mood?

While the drug is primarily associated with nervous system effects like drowsiness, certain literature has noted reports of potential influences on mood states, such as depression or anxiety, suggesting this is an area of study.


Q: Do studies suggest Coolips is more effective in certain age groups?

Official documentation supports different dosing regimens for adults, adolescents, and children based on age and health status. Effectiveness is established across these studied age groups, but regulatory sources do not contain comparative claims about one age group being more effective than another.


Q: If I stop taking Coolips, are there specific withdrawal effects described?

Regulatory warnings describe that severe generalized itching (pruritus) may occur after stopping the daily use of the medication, particularly following long-term administration. This is a known post-discontinuation symptom described in the official safety profile.


Q: How long does the effect of a single dose of Coolips last?

As a second-generation antihistamine taken once daily, the duration of the pharmacological action of a single dose is typically described as lasting for about 12 to 24 hours. This time frame is aligned with the drug's established once-daily dosing schedule.


Q: Will I need to have regular blood tests while taking Coolips?

Regular blood tests for monitoring the drug itself are generally not required while taking Coolips. However, regulatory guidance for allergy skin testing advises that the medication must be stopped for several days before a skin prick test is administered to ensure accurate results.


Q: Is Coolips a controlled substance?

Coolips (Cetirizine) is officially classified by regulatory authorities in the United States and other regions as Not a controlled medication.


Q: Does Coolips require a prescription?

The status of the medication depends on its form. The Intravenous (IV) formulation of Coolips is listed as a Prescription only medicine. The common oral formulation (Cetirizine) often varies by dose and local regulatory rules but is frequently available over-the-counter (OTC) in certain strengths.

How should Coolips be stored and disposed of?

How to Store and Dispose of Coolips?

Coolips (Cetirizine Hydrochloride) requires specific storage and disposal practices as defined in official regulatory labeling to maintain its stability and ensure environmental protection.


Official Storage Requirements

Storage Domain Regulatory Requirement
Temperature Control Store the product at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), and must not exceed 30 C.
Environmental Protection Keep Coolips away from excess heat and moisture. The tablets do not require any special storage conditions beyond these guidelines.
Packaging Always keep the medicine in its original container, tightly closed, and do not use if the seal or blister pack is broken.
In-Use Stability The oral solution form has an in-use shelf-life of 6 months after the initial opening, provided it is stored at or below 25 C.

Mandatory Disposal and Safety

Child-Protection Mandate: Coolips must be stored out of the sight and reach of children at all times.

Disposal Instructions: Disposal of unused or expired Coolips must be done in accordance with local requirements for pharmaceutical waste. Medicine should not be thrown away via household waste or flushed down wastewater, as this helps to protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Coolips found in:

A-Z Index: